Skip Nav Destination
Issues
15 January 2009
-
Cover Image
Cover Image
Specific small-molecule inhibitors of MEK are promising anticancer agents targeting the oncogenic RAF-MEK-ERK pathway. Breast cancer, as in most solid malignancies, is a phenotypically and molecularly heterogeneous disease. It is unclear whether individual breast cancer subtypes are particularly susceptible to these agents. Mirzoeva and colleagues used a systems-based approach to identify such subtypes and to understand molecular mechanisms conferring resistance to MEK inhibitors. Basal-type breast cancer cells were found to be particularly susceptible to growth-inhibition by small-molecule inhibitors. The cover image demonstrates results of an mRNA expression array analysis of MEK-related gene predictors of response to MEK inhibitors. Genes in the upper panel predict sensitivity to MEK inhibitors, whereas those in the lower panel predict resistance. In the tree, yellow end-nodes denote basal-type cell lines and pink end-nodes denote luminal cell lines. These data, in conjunction with the additional finding of interconnectivity between the MEK and PI3 kinase signal transduction pathways, have implications for future clinical trials of MEK inhibitors and also suggest rationally designed combination therapies. For details, see the article by Mirzoeva and colleagues on page 565 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 0008-5472
EISSN 1538-7445
Issue Sections
Journal Archive
Cancer Research (1941-Present; volumes 1-current)
(ISSN 0008-5472) Published twice monthly since 1987. From 1941-1986, published monthly.The American Journal of Cancer (1931-1940; volumes 15-40)
(ISSN 0099-7374) Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.The Journal of Cancer Research (1916-1930); volumes 1-14)
(ISSN 0099-7013) Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.Table of Contents
AACR Centennial Series
Reviews
Meeting Reports
Priority Reports
Cell, Tumor, and Stem Cell Biology
De novo Induction of Genetically Engineered Brain Tumors in Mice Using Plasmid DNA
Stephen M. Wiesner; Stacy A. Decker; Jon D. Larson; Katya Ericson; Colleen Forster; Jose L. Gallardo; Chunmei Long; Zachary L. Demorest; Edward A. Zamora; Walter C. Low; Karen SantaCruz; David A. Largaespada; John R. Ohlfest
Tenascin-C Is a Novel RBPJκ-Induced Target Gene for Notch Signaling in Gliomas
Balasubramanian Sivasankaran; Martin Degen; Anthony Ghaffari; Monika E. Hegi; Marie-France Hamou; Mihai-Constantin S. Ionescu; Christian Zweifel; Markus Tolnay; Morten Wasner; Susanne Mergenthaler; André R. Miserez; Robert Kiss; Maddalena M. Lino; Adrian Merlo; Ruth Chiquet-Ehrismann; Jean-Louis Boulay
Endocrinology
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
Olga K. Mirzoeva; Debopriya Das; Laura M. Heiser; Sanchita Bhattacharya; Doris Siwak; Rina Gendelman; Nora Bayani; Nicholas J. Wang; Richard M. Neve; Yinghui Guan; Zhi Hu; Zachary Knight; Heidi S. Feiler; Philippe Gascard; Bahram Parvin; Paul T. Spellman; Kevan M. Shokat; Andrew J. Wyrobek; Mina J. Bissell; Frank McCormick; Wen-Lin Kuo; Gordon B. Mills; Joe W. Gray; W. Michael Korn
Epigallocatechin-3-Gallate, a Histone Acetyltransferase Inhibitor, Inhibits EBV-Induced B Lymphocyte Transformation via Suppression of RelA Acetylation
Kyung-Chul Choi; Myung Gu Jung; Yoo-Hyun Lee; Joo Chun Yoon; Seung Hyun Kwon; Hee-Bum Kang; Mi-Jeong Kim; Jeong-Heon Cha; Young Jun Kim; Woo Jin Jun; Jae Myun Lee; Ho-Geun Yoon
Immunology
Quantitative DNA Methylation Analysis of FOXP3 as a New Method for Counting Regulatory T Cells in Peripheral Blood and Solid Tissue
Georg Wieczorek; Anne Asemissen; Fabian Model; Ivana Turbachova; Stefan Floess; Volker Liebenberg; Udo Baron; Diana Stauch; Katja Kotsch; Johann Pratschke; Alf Hamann; Christoph Loddenkemper; Harald Stein; Hans Dieter Volk; Ulrich Hoffmüller; Andreas Grützkau; Alexander Mustea; Jochen Huehn; Carmen Scheibenbogen; Sven Olek
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Lawrence Fong; Serena S. Kwek; Shaun O'Brien; Brian Kavanagh; Douglas G. McNeel; Vivian Weinberg; Amy M. Lin; Jonathan Rosenberg; Charles J. Ryan; Brian I. Rini; Eric J. Small
Molecular Biology, Pathobiology, and Genetics
Helicobacter pylori Cytotoxin-Associated Gene A Activates the Signal Transducer and Activator of Transcription 3 Pathway In vitro and In vivo
Dana M. Bronte-Tinkew; Mauricio Terebiznik; Aime Franco; Michelle Ang; Diane Ahn; Hitomi Mimuro; Chihiro Sasakawa; Mark J. Ropeleski; Richard M. Peek, Jr.; Nicola L. Jones
Chromosomal Signatures of a Subset of High-Grade Premalignant Cervical Lesions Closely Resemble Invasive Carcinomas
Saskia M. Wilting; Renske D.M. Steenbergen; Marianne Tijssen; Wessel N. van Wieringen; Theo J.M. Helmerhorst; Folkert J. van Kemenade; Maaike C.G. Bleeker; Mark A. van de Wiel; Beatriz Carvalho; Gerrit A. Meijer; Bauke Ylstra; Chris J.L.M. Meijer; Peter J.F. Snijders
High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast Tumors
Elodie Manié; Anne Vincent-Salomon; Jacqueline Lehmann-Che; Gaelle Pierron; Elisabeth Turpin; Mathilde Warcoin; Nadège Gruel; Ingrid Lebigot; Xavier Sastre-Garau; Rosette Lidereau; Audrey Remenieras; Jean Feunteun; Olivier Delattre; Hugues de Thé; Dominique Stoppa-Lyonnet; Marc-Henri Stern
Prevention
Systems Biology and Emerging Technologies
Letters to the Editor
Correction
Advertisement